Dr Craig Gedye

BSc(Hons), MBChB, FRACP, PhD
Medical Oncologist
Become a Patient

Dr Craig Gedye is an experienced medical oncologist and scientific researcher, committed to providing the highest level of care for people with cancer. He has a strong focus on partnering with patients and researchers to improve treatments and health outcomes through clinical trials.


Dr Craig Gedye is a medical oncologist at Icon Cancer Centre Adelaide and the Director of Research (Haematology and Medical Oncology) for Icon Group. He holds a Bachelor of Science (BSc) with First Class Honours in Chemistry from the University of Canterbury, New Zealand (1992), Bachelor of Medicine and Bachelor of Surgery (MBChB) with distinctions from the University of Otago, New Zealand (1996) and a Doctor of Philosophy (PhD) in cancer biology from the University of Melbourne (2009).

Dr Gedye undertook specialist medical oncology fellowship training across hospitals in Melbourne and Christchurch, New Zealand and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 2004.

He enjoys a mixture of clinical practice and research, serving people with cancer on a personal basis as well as working with consumers, clinicians, researchers and partners to improve health outcomes. This includes research focused on the patient’s experience of cancer and cancer treatment, through to clinical trials and translational science. His research focuses on a key problem for people with cancer; why do treatments work for one patient, and not others? By studying complexity and heterogeneity in cancer, he hopes to improve treatments and outcomes for everyone facing cancer.

As well as being a site Investigator for numerous commercial and cooperative group trials, Dr Gedye is the Study Chair for several investigator initiated clinical trials for brain and urological cancers, and is the Chair of the Kidney Cancer Subcommittee of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group. In partnership with organisations including the ANZUP Cancer Trials Group and Cooperative Trials Group for Neuro-Oncology (COGNO), Dr Gedye has led the ANZadapt, MAGMA, UNISON, EnzAdapt and KeyPAD clinical trials.

He has published over 80 manuscripts, 70 conference proceedings, and 40 national and international speaking engagements. He also serves as a journal reviewer for esteemed publications and is an active member of health research ethics and scientific advisory committees for various national and international organisations.

Dr Gedye has practised as a medical oncologist in various public and private hospitals in Victoria, New South Wales, New Zealand and Canada. He is currently Director of Research for Medical Oncology and Haematology at Icon Group and Chair of the ANZUP Renal Cancer Subcommittee, and has held leadership positions in clinical and cancer research including Associate Director of the HMRI Clinical Trials Unit and Clinical Research Director of NSW Statewide Biobank.

His clinical experience covers a wide range of solid tumour malignancies, with a special interest in melanoma, bladder cancer, brain cancer, kidney cancer and prostate cancer. To connect with Dr Gedye on LinkedIn, you can find his profile here.

Podcasts featuring Dr Gedye

Cancer Council | What Does Advanced Cancer Mean?
The Oncology Podcast | What is Adaptive Therapy? ANZadapt Trial with Craig Gedye

Affiliations & Memberships

  • American Society for Clinical Oncology (ASCO)
  • Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group
  • Cooperative Trials Group for Neuro-Oncology (COGNO)
  • Medical Oncology Group of Australia (MOGA)


Special Interests

Dr Craig Gedye accepts referrals for all cancer types, with a special clinical interest in:
  • Bladder cancer
  • Brain and spine (CNS) cancer
  • Genitourinary cancer
  • Melanoma
  • Prostate cancer

Icon Locations

Adelaide (Kurralta Park) View centre

Visiting Locations

  • St Andrew’s Medical Centre


    • An immune atlas of clear cell renal cell carcinoma. Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, Ries CH, Ailles L, Jewett MAS, Moch H, van den Broek M, Beisel C, Stadler MB, Gedye C, Reis B, Pe’er D, Bodenmiller. B. Cell. 2017 May 4; 169(4): 736-749. e18.
    • Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma. Kong BY, Sim HW, Barnes EH, Nowak AK, Hovey EJ, Jeffree R, Harrup R, Parkinson J, Gan HK, Pinkham MB, Yip S, Hall M, Tu E, Carter C, Koh ES, Lwin Z, Dowling A, Simes JS, Gedye C. BMJ Open. 2022 Sep 14; 12(9): e058107.
    • Depatuxizumab-mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A, Curran WJ, Mehta MP. Neuro Oncol. 2022 Jul 15: no ac 173.
    • Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Özgüroǧlu M, Matsubara N, Gedye C, Choi YD, Padua C, Kohlmann A, Huisden R, Elvin JA, Kang J, Adelman CA, Allen A, Poehlein C, de Bono. J.Clin Cancer Res. 2022 Apr 14; 28(8): 1518-1530.